NICE’s Preparations for Evaluating New Alzheimer’s Treatments

By Staff Writer

December 27, 2023

The Advent of Disease-Modifying Dementia Treatments (DMDTs)

Recent years have seen significant strides in our understanding of dementia, particularly Alzheimer’s disease. These advancements have led to the development of Disease-Modifying Dementia Treatments (DMDTs). These treatments aim to alter the course of disease progression and reduce its severe impact. Currently, the UK has not licensed any DMDTs, but several are undergoing various stages of development and approval. The National Institute for Health and Care Excellence (NICE) will be evaluating new Alzheimer’s treatments, namely, lecanemab and donanemab, next year. 

Preparing for the Evaluating New Alzheimer’s Treatments

In preparation for the evaluation of these innovative treatments, NICE, in collaboration with the NHS and patients, has initiated work to identify potential issues that may arise during planned and future evaluations. This work is being carried out by NICE’s Health Technology Assessment Innovation Laboratory (HTA Lab) and is based on current knowledge, publicly available evidence, and in-depth discussions with researchers, patient groups, and NHS colleagues.

Key Issues to Consider in the Appraisal Process

The report highlights several issues that require attention in a comprehensive appraisal process. One issue is the uncertainty surrounding the number of people with mild cognitive impairment. Another concern is the present need for invasive tests to determine eligibility for new treatments. Lastly, there’s a critical lack of data on the long-term effectiveness of DMDTs currently published. Extensive assumptions will be required to extrapolate results from current research trials to infer the lifetime benefit of DMDTs in terms of quality and length of life.

Economic Modelling Considerations and the Future of Dementia Treatment

Economic modelling considerations also come into play. DMDTs are expected to be administered by intravenous infusions in hospitals, and the economic models will need to include these additional costs. Despite these challenges, NICE’s methods and processes for technology appraisal continue to be suitable for assessing these innovative new treatments.

The development of disease-modifying treatments for dementia represents a long-awaited change in the management of a condition associated with a considerable burden of illness. The UK is at the forefront of this research, and these new treatments represent potentially significant advancements in the field.

Reference url

Recent Posts

Egypt Hepatitis C Program
     

Egypt’s Hepatitis C Program: A Model for Africa’s Health Initiatives

🌍 How can Egypt’s hepatitis C elimination program inspire other African nations?

Discover how Egypt has set a powerful benchmark for public health excellence through its “100 million Healthier Lives” campaign, achieving Gold-tier certification from the WHO. This article looks into the training initiatives and regional collaboration that are paving the way for health improvements across the continent.

#SyenzaNews #GlobalHealth #HealthcareInnovation #Innovation #HealthForAll

Maturity Level 3 regulation
      

Maturity Level 3 in Medicines Regulation in Senegal and Rwanda

🌍 How do robust regulatory systems impact public health globally?

Senegal and Rwanda have made significant strides by achieving WHO Maturity Level 3 in medicines regulation, enhancing their capability to ensure safe and effective medical products. This accomplishment not only fortifies local health standards but also sets a benchmark for other nations to follow, promoting regional collaboration and economic benefits. Discover how this achievement will impact global health outcomes!

#SyenzaNews #globalhealth #regulatoryaffairs #MarketAccess #innovation

95-95-95 HIV targets
     

Advancing the 95-95-95 Targets: A Roadmap to End AIDS by 2030

🌍 How close are we to achieving the **95-95-95 HIV targets**?

Explore the latest insights from UNAIDS on the progress and strategic importance of these targets in ending the HIV/AIDS pandemic by 2030. The framework not only focuses on comprehensive testing and treatment but also emphasizes equity in healthcare access across all demographics.

Read more about how we can collectively strive for a future free from HIV/AIDS-related stigma and health inequities.

#SyenzaNews #GlobalHealth #HealthcareInnovation #Healthforall #FutureofHealthcare

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.